Human growth hormone (hGH) is frequently used clinically for growth abnormalities in children and also in adults with growth hormone deficiency. The hormone is usually administered to the individuals by fre quent injections. In the present study we investigated the potential of bone marrow stromal cells as vehicles to deliver the GH in vivo by infusion of cells transduced with hGH cDNA into mice femurs. The effect of the hormone on the transduced cells in vitro was also assessed. Bone marrow stromal cells established from a mouse model of human osteogenesis imperfecta mice (oim) were transduced with a retrovirus containing hGH and neomycin resistance genes. The hGH-expressing cells were selected in a medium containing G418 and were then assessed for the hGH expression in vitro. The selected cells synthesized 15 ng/10 6 cells of hGH per 24 h in vitro and exhibited alkaline phosphatase activity when they were treated with the human recombinant bone morphogenetic protein 2 (rhBMP-2). The transduced cells also proliferated faster than the LacZ transduced cells but they did not exhibit a higher rate of matrix synthesis. When 2 x 10 6 hGH+ cells were injected into the femurs of mice, hGH was detected in the serum of the recipient mice up to 10 days after injection. The highest level of growth hormone expression, 750 pg/ml, was detected in the serum of the recipient mice 1 day after injection of the transduced cells. hGH was also detected in the medium conditioned by cells that were flushed from the femurs of the recipient mice at 1, 3, and 6 days after cell injection. These data indicate that bone marrow stromal cells could potentially be used therapeutically for the delivery of GH or any other therapeutic proteins targeted for bone. The data also suggest that GH may exert its effects on bone marrow stromal cells by increasing their rate of proliferation.
INTRODUCTION
Somatic gene therapy has great potential for the treat ment of a variety of diseases both genetic and acquired.
It is also being investigated as a means of delivering therapeutic proteins to specific organs or tissues within the body or into the circulatory system (5, 11, 22, 29) , for example, growth factors to augment fracture healing (28, 33) , delivery of anti-inflammatory cytokines in a clinical trial of rheumatoid arthritis (14, 16) , and in augmentation of healing of other connective tissues (13) (14) (15) . Presently, therapeutic proteins are routinely admin istered to patients by repeated intravenous or subcutane ous infusions. In addition, there are a number of clinical trials in which the proteins are administered by frequent injections to the patients. One such protein is growth hormone (GH), used clinically to treat children with growth deficiency due to the lack of the hormone pro duction and also in adults with low levels of GH produc tion (6, 27, 38, 39) . GH is considered to be one of the fac tors controlling longitudinal bone growth, presumably through the induction of IGF-1 (9, 12, (23) (24) (25) . Clinical trials with GH have been carried out in patients with osteoporosis to assess the effect of this hormone on ma trix synthesis and bone mineral density (1, 2) . The pro gressive decline in GH secretion is considered to be among the factors contributing to the age-related post menopausal bone loss (20, 37) . This has led some inves tigators to suggest that GH could potentially be used as a therapeutic agent for osteoporosis (25) .
Among individuals with osteogenesis imperfecta (OI), growth deficiency is a common finding (30) . How (3, 30) . In all these clinical trials, the GH is ad ministered by daily injection. In the present study, we evaluated the potential of bone marrow stromal cells es tablished from a mouse model of 01 (10) to serve as vehicles to deliver and express the hormone in vivo. The hypothesis is that delivery of the GH in vivo by bone marrow stromal cells would offer sustained GH expres sion and would also target the hormone to the desired site.
Bone marrow stromal cells were established from the marrow harvested from the femurs and tibias of os teogenesis imperfecta mice (oim) (4, 10, 30) . When these cells were transduced with the LacZ marker gene and suspended in ceramic cubes they synthesized bone and cartilage, and they persisted in bone when they were injected in oim mice femurs (34) . We have transduced these cells with human growth hormone gene to assess the effect of the hormone on cells and also the potential of the cells to deliver and express the hormone in bone and in systemic circulation. A single injection of autolo gous bone marrow stromal cells engineered to express and produce GH would offer an alternate approach for the delivery of the hormone to the affected individuals.
MATERIALS AND METHODS

Cell Preparation
Bone marrow was flushed the from the femurs and tibias with Dulbecco's modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin (P/S), and 1% L-glutamine as previously described (4, 34) . Briefly, cells were passed through a 21-gauge needle several times and washed by centrifugation in DMEM supplemented with 10% FBS and 1% P/S. The cells were then seeded into T-25 flasks in the above medium and incubated at 37°C in 5% C0 2 and allowed to adhere to the flasks without disturbance for 7 days. All nonadherent cells were then removed and the adherent cells were main tained in culture with medium changes every 3 days.
Transduction of Bone Marrow Stromal Cells With a
Retrovirus Encoding the Human Growth Hormone and Neomycin Resistance Genes
The established long-term bone marrow stromal cells were grown to 60% confluence in T- 25 Bone marrow stromal cells that were transduced with the BAG retrovirus were treated similarly and served as controls.
Alkaline Phosphatase Activity of the Transduced Cells
The hGH and the LacZ transduced cells were plated in six-well plates. After 24 h, the medium was replaced with medium supplemented with 100 ng/ml of rhBMP- 
Collagen Synthesis by the Transduced Bone Marrow
Stromal Cells
Bone marrow stromal cells transduced with hGH and Neo r genes or LacZ and Neo r genes were plated in six-well plates. When the cells reached confluence, the me dium was removed and replaced with serum-free me dium containing 50 pg/ml ascorbic acid, 50 pg/ml betaamino-propionitrile, and 20 pCi of [ 3 H]proline/ml for 24 h. After incubation, conditioned medium and cell layer were collected and combined and the relative collagen synthesis was determined by [ 3 H]proline incorporation using a modified collagenase digestion method (7, 36) . Briefly, after 24 h of culture in the presence of the radio isotope, a 200-pl aliquot was removed from the com bined medium and cell layer of each well for DNA quantitation. To the rest of the sample, a carrier protein (2 mg/ml of pepsin-solubilized bovine type I collagen) was added and the proteins were precipitated by addition of 10% trichloroacetic acid (TCA). The TCA-precipitated proteins were recovered by centrifugation at 14,000 rpm for 30 min at 4°C. The recovered protein pellets were washed repeatedly with 5% TCA to remove the unbound isotope. After repeated washing with TCA, the pellets were resuspended in the collagenase buffer (5 mM CaCl 2 and 3 mM N-ethylmaleimide), the pH was adjusted to 7, and pellets were incubated at 37°C for 2 h. After 2-h incubation, TCA was added and the mixture was centrifuged for 30 min at 14,000 rpm. The superna tants were removed and were used as enzyme blanks. The pellets were resuspended in the collagenase buffer and purified bacterial collagenase ABC form III (Ad vanced Biofactures, Lynbrook, NY) was added (20 U/ ml) and incubated for 2 h at 37°C. The collagenase-digestible proteins were separated from nondigested pro teins by addition of 5% TCA followed by centrifugation at 14,000 rpm for 30 min. The pellets were redissolved in 0.2 M NaOH and aliquots of the pellets and the super natants were subjected to the radioactive counting to de termine the level of collagen and noncollagenous protein synthesis. The data were corrected for variation in DNA concentration. The experiment was performed three times in triplicate.
Cell Proliferation
An equal number of oim bone marrow stromal cells (1 x 10 4 ) transduced with either hGH or LacZ gene were plated in six-well plates and incubated for 72 h at 37°C in 5% C0 2 . After 72 h of culture, cells were trypsinized and cell numbers were counted. The increase in cell number between different wells was taken as an indica tion of the rate of cell proliferation. The experiment was performed three times in triplicate.
DNA Quantitation
For DNA measurements, at the end of each experi ment, the medium and the cells were combined and ho To determine whether cells transduced with the hGH gene would express it in vivo, cultured bone marrow stromal cells of oim mice were trypsinized, collected into GBSS, and prepared for injection into the femurs of oim mice. Before cell injection, blood was collected from the tail vein of the mice that received the hGH+ cells. The GH concentrations in sera collected before the hGH+ cell infusion served as background of the endoge nous GH synthesized by each recipient mouse. For cell injection, the mice were anesthetized by metafane inha lation and an incision was made above the knee joint to expose the femoral condyles. Cells (2x 10 6 ) in 50 pi GBSS were injected through the femoral condyles into the femurs of oim mice using a 25-gauge needle. Five mice were injected with the hGH+ cells and blood was collected via the tail vein at 4 h and at 1, 3, 6, and 10 days after cell infusion.
Determination of the hGH Concentration in the Serum of oim Mice That Received the Transduced Cells
Blood samples were collected from the tail vein of each mouse that received the hGH+ cells at the time points of 4 h, and 1, 3, 6, and 10 days postinjection. hGH levels in the serum of the recipient mice were de termined using the hGH ELISA kit. Aliquots (20 pi) of serum from each mouse that received the hGH+ cells were used for the GH determination. The GH values measured in the serum of each of the recipient mice prior to cell injection were subtracted from the values determined from the test samples and the resulting levels were taken as the hGH concentrations synthesized by the injected cells.
Recovery of the hGH Transduced Cells From the Recipient Mice
To determine whether the hGH+ cells were in bone, mice femurs were injected with 2 x 10 6 hGH+ cells and the recipient mice were sacrificed at 1, 3, and 6 days after cell injection. The cells were recovered by flushing the marrow from the injected femurs and the contralat eral femurs of the recipient mice. The marrow cells were cultured at 37°C in 5% CQ 2 in oc-MEM supplemented with 20% FBS, 1% P/S for 7 days without disturbance. On day 7, the medium was removed and assayed for the hGH expression. Cells were transferred to a-MEM containing 0.5 mg/ml of G418 to select and confirm the presence of cells that were expressing hGH. The se lected cells were assayed for GH expression and ALP activity.
RESULTS
hGH Production
In Vitro by the Transduced Cells
The hGH+ cells and the LacZ cells in terms of collagen and noncollagenous protein synthesis (Fig. 3A, B ).
Cell Proliferation
Although there was no difference between hGH and LacZ transduced cells in terms of matrix synthesis, the GH transduced cells proliferated faster than the LacZ transduced cells. Figure 4 shows the increase in cell 
Recovery of the hGH Transduced Cells From the
Recipient Mice
To demonstrate that the cells expressing the hGH were in bone, marrow was flushed from the femurs of the mice that received the hGH transduced cells. The cells recovered from the injected femur at day 1 postin-
Days after cell infusion Figure 5 . In vivo production of hGH by the transduced cells. Transduced cells were injected in the femurs of oim mice. ELISA was used to detect the presence of the hGH in the serum of the recipient mice at 1, 3, 6, and 10 days after cell injection. Each time period represents data from five mice that received the hGH+ positive cells. At day 1 after cell injection, all five mice that received the hGH+ cells demonstrated the presence of hGH in their sera. The serum collected from each mouse before cell injection was used to measure the endogenous hGH. The values were subtracted from the hGH concentration measure ments obtained after cell infusion. Each hash bar represents the mean of GH concentration for n = 5 samples.
jection and selected in a medium containing G418 syn thesized 3500 pg/ml of the hGH over 24 h (Table 1) . This level is comparable to the amount synthesized by the cells that were maintained in culture, which synthe sized 4000 pg/ml over 24 h. All the cells were cultured in T-25 flasks with 4 ml of medium, and the medium was analyzed for GH concentration at confluence. The 15 ND Cells were flushed from the femurs of the mice that received the transduced cells at 1,3, and 6 days after cell injection. hGH concentration was assessed by ELISA. N=2\ average hGH concentration in the medium conditioned by the cells flushed from the femurs of two different mice is indicated. ND: not determined.
cells recovered from the femurs of the mice that re ceived the hGH+ cells at day 3 after cell injection dem onstrated synthesis of hGH in culture at a concentration of 120 pg/ml before selection. After selection the cells synthesized the hGH at a concentration equivalent to the level of the hGH synthesized by the cells recovered at day 1 and selected in G418. The cells recovered from the contralateral femurs at 1 and 3 days after injection did not synthesize any hGH. At day 6 postinjection, however, the cells recovered from the injected femurs and contralateral femurs synthesized very low levels of hGH ranging from 10 to 25 pg/ml, suggesting that by day 6 after injection the cells trafficked through the cir culatory system and occupied other organs, including contralateral femurs. The sensitivity of the hGH kit is 5 pg/ml. The data agree with our previous observations that bone marrow stromal cells infused into femurs of mice trafficked through the circulatory system and were detected in the contralateral femurs of the same mice (34) . The recovered cells also expressed ALP activity (data not shown). Figure 6 shows the morphological ap pearance of the recovered cells at day 3 postinjection before ( Fig. 6a ) and after ( Fig. 6b ) selection in G418, confirming the presence of the hGH+ cells.
DISCUSSION
In the present study we have shown that bone marrow stromal cells retrovirally transduced with the hGH cDNA express the gene at high levels in vitro and in vivo. The expression of the hGH in vitro by bone mar row stromal cells was maintained at high levels even after 10 passages without any sign of diminished hGH synthesis when the cells were cultured in the presence of G418. In addition, the hGH was detected in the serum of the mice that received the hGH-i-cells at 1,3, 6, and 10 days after cell infusion. It has been estimated that the half-life of exogenously administered GH in humans ranges from 9 to 26 min and in mice it is 4 min (18, 19, 35) . The fact that the hGH was detected in the mice up to 10 days after injection suggests that there was a continuous synthesis of this hormone by the in jected cells. In the present study only 2 x 10 6 cells trans duced with the hGH gene were injected in the mice fe murs; by day 1 after cell injection, the concentration of hGH detected in the serum of the recipient mice ranged from 200 to 750 pg/ml. This level of hGH expression is quite high when compared to the physiological levels of GH in human plasma, which are estimated to range from 100 to 250 pg/ml (35) . Use of bone marrow stromal cells would therefore offer an advantage over daily GH injec tions in that the transduced cells would provide sus tained expression of the hormone. In addition, the cells producing the hormone would be in bone, the site where the GH would be needed. This is especially important 0 C Figure 6 . Morphological appearance of the cells recovered at day 3 after cell injection, (a) Cells recovered at day 3 after injection and maintained in culture for 7 days, (b) Appearance of the cells recovered at day 3 of cell injection and after selection in medium containing G418, indicating presence of hGH+ cells.
in cases of OI and osteoporosis, because the target of the hormone is the bone cells or osteoprogenitor cells. Other cell types besides bone marrow stromal could be potentially used to deliver the GH in vivo [e.g., my oblasts (5, 11) or fibroblasts (8) ]. The advantage of using the bone marrow stromal cells is that the target of the GH is bone cells or osteoprogenitor cells and therefore the injected cells would not only deliver the GH but would also participate in bone formation.
The expression of the hGH in the serum of the mice that were injected with the GH+ cells was not detected in any of the mice beyond 10 days after cell infusion.
Several factors could account for the loss of hGH ex pression in the recipient mice. First, the cells injected in the mice are expressing a human protein, which could illicit immune response in the recipient mice. Second, the viral promoter may be shut off by poorly understood mechanisms. Third, the cells could have been elimi nated. Although these possibilities were not tested in the present investigation, the first possibility is supported by the observation that implantation of the encapsulated fi broblasts expressing the hGH in mice elicited immune response 2 weeks after implantation. The immune re sponse was detected against the hGH and not any other products from the cell (8). These observations suggest that the dramatic drop-off in hGH expression in the se rum of the recipient mice is most likely due to the im mune response elicited by the mice against the hGH. Hurwitz et al. (22) infused autologous bone marrow stromal cells transfected with an expression plasmid containing human GH or factor IX in dogs. The hGH was detected in the sera of the recipient dogs within 15 min after cell infusion (22) . PCR amplification of DNA from the tissues of the dogs that received the GH+ cells demonstrated that the GH transfected cells persisted in the tissues of the recipient dogs although the GH was not detectable. Although in this study the authors used expression plasmids, which give transient expression of the inserted genes, their data suggest that cells can per sist in tissues even though the inserted genes are not being expressed. It is therefore possible that in the pres ent study the GH gene could have been inactivated de spite the presence of the cells. The present study did not investigate these possibilities but they are the likely explanation for the lack of GH detection in the sera of the recipient mice beyond 10 days.
The rapid decline of the GH expression could poten tially be overcome by the use of autologous bone mar row stromal cells transduced with the specifies specific GH gene. In addition, bone-specific promoters could be used to drive the GH gene expression in bone. Use of bone-specific promoters (e.g., osteocalcin promoter) would aid in targeting the cells to bone. If these cells are to be used therapeutically, bone marrow stromal cells would be harvested from an individual, genetically modified by transduction with hGH gene, and then re turned to the same individual. Engraftment of cells from the marrow that are capable of participating in bone for mation has been demonstrated in mice (32) and in chil dren with severe OI (21). The engraftment of the cells in mice was demonstrated to occur without marrow ab lation. In the children with severe OI, the cells trans planted were from a donor and therefore the recipients had to be irradiated before bone marrow transplantation. However, the study demonstrated that the transplanted cells participated in bone formation because there ap peared to be an improvement in the bone quality of the patients that received the normal bone marrow trans plants (21) . These cells therefore would be ideal candi dates for the delivery of the GH in bone tissue as an alternative to daily GH injections.
The limitation of the presented study is that primary bone marrow stromal cells were not used for the deliv ery of GH. However, the cells used here have been char acterized and have been shown to be pluripotent (34). The cells have been shown to exhibit potential to form bone and cartilage in vivo and to express osteoblast phe notype only when they are treated with rhBMP-2 (4,34). If this technology could be adopted to human use, pri mary cells would have to be used. Although transduction of primary bone marrow stromal cells with retroviral vectors is not as efficient as cell lines, it has been re ported that higher transduction efficiency could be achieved by multiple transduction of the cells with the gene of interest (31).
In summary, these data indicate that bone marrow stromal cells may be used as vehicles for the delivery of therapeutic proteins in vivo. The cells may offer an alternative approach for the delivery of the GH or any other therapeutic proteins in vivo.
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